NVO Aug 2024 139.000 call
- Yahoo Finance Video
Biden, Sanders call for obesity drug makers to cut prices
President Biden and Sen. Bernie Sanders (D-Vt.) are calling for price cuts on popular GLP-1 weight-loss drugs. Pharmaceutical stocks Novo Nordisk (NVO) — who makes Ozempic and Wegovy — and Eli Lilly (LLY) — who makes Mounjaro and Zepbound — tilt lower on the news. Yahoo Finance Health Reporter Anjalee Khemlani details the political discourse around these obesity treatments, citing President Biden and Senator Sanders' op-ed published in USA Today. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
- Bloomberg
Ozempic Linked to Rare Cases of Vision Loss in Harvard Study
(Bloomberg) -- Novo Nordisk A/S’ best-selling diabetes and weight-loss drugs Ozempic and Wegovy appears to be associated with a higher risk of a rare form of vision loss, according to an analysis by doctors at Massachusetts Eye and Ear, a Harvard-affiliated hospital.Most Read from BloombergUS Allies Say China Is Developing Attack Drones for RussiaChina Can End Russia’s War in Ukraine With One Phone Call, Finland SaysZelenskiy Challenges Trump to Reveal Plans for Ending WarDemocrats Weigh Mid-Jul
- Insider Monkey
Should You Hold Novo Nordisk A/S (NVO) for the Long Term?
Artisan Partners, an investment management company, released its “Artisan Global Equity Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The expectation of rate reduction later this year and slowing inflation boosted global markets in Q1. In the first quarter, the fund’s Investor Class ARTHX returned 12.67 %, Advisor […]
